Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ilaria Piga

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Journal of Experimental & Clinical Cancer Research : CR|December 20, 2024
Pathogenic mitochondrial DNA variants are associated with response to anti-VEGF therapy in ovarian cancer PDX modelsDaniele Boso, Ilaria Piga, Chiara Trento, et al.
Iscience|December 16, 2025
Organoid platinum-resistance model identifies KRT17 as a biomarker of targeted therapy in ovarian cancerJuliane Reichenbach, Juliana Schmid, Sophia Hierlmayer, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 7, 2023
Anti-VEGF therapy selects for clones resistant to glucose starvation in ovarian cancer xenograftsDaniele Boso, Martina Tognon, Matteo Curtarello, et al.
The International Journal of Biological Markers|November 8, 2024
Impact of metabolism-related markers on outcomes in ovarian cancer patients: Findings of the MITO16A/MaNGO-OV2 trialStefano Indraccolo, Simona Signoriello, Ilaria Piga, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Journal of Experimental & Clinical Cancer Research : CR|December 20, 2024
Pathogenic mitochondrial DNA variants are associated with response to anti-VEGF therapy in ovarian cancer PDX modelsDaniele Boso, Ilaria Piga, Chiara Trento, et al.
Iscience|December 16, 2025
Organoid platinum-resistance model identifies KRT17 as a biomarker of targeted therapy in ovarian cancerJuliane Reichenbach, Juliana Schmid, Sophia Hierlmayer, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 7, 2023
Anti-VEGF therapy selects for clones resistant to glucose starvation in ovarian cancer xenograftsDaniele Boso, Martina Tognon, Matteo Curtarello, et al.
The International Journal of Biological Markers|November 8, 2024
Impact of metabolism-related markers on outcomes in ovarian cancer patients: Findings of the MITO16A/MaNGO-OV2 trialStefano Indraccolo, Simona Signoriello, Ilaria Piga, et al.
Pageof 2